abstract |
The present invention relates to the use of EP4 receptor ligands for the manufacture of a medicament for the treatment of IL-6 related diseases. In addition, the present invention comprises the steps of culturing the peripheral whole blood cultured using the test compound; And measuring the effect of said compound on PGE2-induced whole blood cell activation. |